Skip to main content

Advertisement

SpringerLink
Log in

Safe utilization of ibrutinib with or without steroids in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Manda S, Dunbar N, Marx-Wood CR, Danilov AV (2015) Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia. Br J Haematol 170(5):734–736

  2. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C et al (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107(3):885–891

    Article  CAS  PubMed  Google Scholar 

  3. Rider TG, Grace RJ, Newman JA (2015) Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia. Br J Haematol. doi:10.1111/bjh.13602

  4. Delgado-Vega A, Sanchez E, Lofgren S, Castillejo-Lopez C, Alarcon-Riquelme ME (2010) Recent findings on genetics of systemic autoimmune diseases. Curr Opin Immunol 22(6):698–705

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y et al (2013) Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122(15):2539–2549

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Singh VK, Mehrotra S, Agarwal SS (1999) The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 20(2):147–161

    Article  CAS  PubMed  Google Scholar 

  7. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B et al (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 107(29):13075–13080

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC et al (2007) Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. ChemMedChem 2(1):58–61

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no competing interests.

Authors’ contribution

R.St.B. wrote the initial manuscript. C.C.H. provided cases and revised the manuscript.

Informed consent

Informed consent was obtained from all patients for being included in the study.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology, London Health Sciences Centre, Room E6-219A, Victoria Hospital, 800 Commissioners Road East, London, Ontario, Canada, N6A 4G5

    Rosanne St. Bernard & Cyrus C. Hsia

Authors
  1. Rosanne St. Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cyrus C. Hsia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cyrus C. Hsia.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

St. Bernard, R., Hsia, C.C. Safe utilization of ibrutinib with or without steroids in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. Ann Hematol 94, 2077–2079 (2015). https://doi.org/10.1007/s00277-015-2487-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2487-8

Keywords

Search

Navigation